Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 30;5(1):1-4.
doi: 10.1016/j.jbo.2015.11.001. eCollection 2016 Mar.

Ibandronate: The loading dose concept in the treatment of metastatic bone pain

Gerrit Steffen Maier  1 , Christian Eberhardt  2 , Andreas Alois Kurth  3
Affiliations

Ibandronate: The loading dose concept in the treatment of metastatic bone pain

Gerrit Steffen Maier et al. J Bone Oncol. .

Abstract

Background/aim: Severe bone pain is experienced by 60-80% of patients with metastatic bone disease, and has a profound impact on quality of life. Therefore, effective pain relief is an important goal in managing metastatic bone disease. Orthopedic surgeons are often challenged with patients presenting with newly diagnosed bone metastases and severe and disabling bone pain. It is important to provide fast and sufficient analgesia. Clinical trials have demonstrated that bisphosphonates reduce effectively and sustained bone pain by approved standard dosage over time. Open label prospective trials have shown that short time high dose i.v. Ibandronate is effective in rapid pain relief in different primary tumors.

Patients and methods: In 33 patients with metastatic bone pain from newly diagnosed skeletal metastases we utilized the loading-dose concept for intravenous ibandronate (6 mg infused over 1 h on 3 consecutive days).

Results: In 33 patients loading-dose ibandronate therapy significantly reduced bone pain within the first 5-7 days (VAS day 0: 6-8 vs. day 7: 3-4). Only 3 patients showed no response concerning a distinct pain reduction within the first days of therapy. There was no increase in pain medication.

Conclusion: This clinical observational study in selected patients with severe metastatic bone pain undergoing an intensive high dosed ibandronate-therapy for a short period demonstrated that loading-dose ibandronate (6 mg i.v., 3 consecutive days) resulted in a reduction of pain within days.

Keywords: Bisphosphonate; Bone metastases; Ibandronate; Pain relief.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
: Mean VAS pain scores.
Fig. 2
Fig. 2
Mean MEDD Index.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Body J.J., Mancini I. Bisphosphonates for cancer patients: why, how, and when? Support. Care Cancer. 2002;10:399–407. - PubMed
    1. Mancini I., Dumon J.C., Body J.J. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J. Clin. Oncol. 2004;22:3587–3592. - PubMed
    1. Janjan N. Bone metastases: approaches to management. Semin. Oncol. 2001;28:28–34. - PubMed
    1. Halvorson K.G., Sevcik M.A., Ghilardi J.R., Sullivan L.J., Koewler N.J., Bauss F., Mantyh P.W. Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer. J. Pain. Symptom Manag. 2008;36:289–303. - PMC - PubMed
    1. Mercadante S. Breakthrough pain: on the road again. Eur. J. Pain. 2009;13:329–330. - PubMed

LinkOut - more resources